The Treatment of Mild and Moderate Asthma in Adults.

BACKGROUND Asthma is a chronic inflammatory airway disease that usually causes variable airway obstruction. It affects 5-10% of the German population. METHODS This review is based on relevant publications retrieved by a selective search, as well as on national and international guidelines on the treatment of mild and moderate asthma in adults. RESULTS The goal of treatment is to attain optimal asthma control with a minimal risk of exacerbations and mortality, loss of pulmonary function, and drug side effects. This can be achieved with a combination of pharmacotherapy and non-drug treatment including patient education, exercise, smoking cessation, and rehabilitation. Pharmacohterapy is based on inhaled corticosteroids (ICS) and bronchodilators. It is recommended that mild asthma should be treated only when needed, either with a fixed combination of ICS and formoterol or with short-acting bronchodilators. For moderate asthma, maintenance treatment is recommended, with an inhaled fixed combinations of ICS and long-acting beta-mimetics, possibly supplemented with longacting anticholinergic agents. Allergen immunotherapy, i.e., desensitization treatment, should be considered if the allergic component of asthma is well documented and the patient is not suffering from uncontrolled asthma. Asthma control should be monitored at regular intervals, and the treatment should be adapted accordingly. CONCLUSION The treatment of asthma in adults should be individually tailored, with anti-inflammatory treatment as its main component.

[1]  M. Lommatzsch Immune Modulation in Asthma: Current Concepts and Future Strategies , 2020, Respiration.

[2]  C. Janson,et al.  Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme , 2020, European Respiratory Journal.

[3]  J. Hoving,et al.  Workplace interventions for treatment of occupational asthma , 2011, TBV – Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde.

[4]  N. Kearns,et al.  Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma , 2020, European Respiratory Journal.

[5]  J. Virchow,et al.  Perspectives in allergen immunotherapy: 2019 and beyond , 2019, Allergy.

[6]  J. Virchow,et al.  Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials , 2019, The Lancet.

[7]  R. Hancox,et al.  Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial , 2019, The Lancet.

[8]  I. Pavord,et al.  Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. , 2019, American journal of respiratory and critical care medicine.

[9]  A. Sheikh,et al.  GINA 2019: a fundamental change in asthma management , 2019, European Respiratory Journal.

[10]  I. Pavord,et al.  Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. , 2019, The New England journal of medicine.

[11]  O. Usmani Choosing the right inhaler for your asthma or COPD patient , 2019, Therapeutics and clinical risk management.

[12]  Xiaohui Xie,et al.  Tiotropium added to low- to medium-dose inhaled corticosteroids (ICS) versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma: A systematic review and meta-analysis , 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.

[13]  J. Virchow,et al.  Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma , 2018, Thorax.

[14]  W. Busse,et al.  Tiotropium add-on to inhaled corticosteroids versus addition of long-acting β2-agonists for adults with asthma. , 2018, Respiratory medicine.

[15]  W. Busse,et al.  Combined Analysis of Asthma Safety Trials of Long‐Acting β2‐Agonists , 2018, The New England journal of medicine.

[16]  E. Bateman,et al.  Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma , 2018, The New England journal of medicine.

[17]  C. White,et al.  Association of Inhaled Corticosteroids and Long-Acting &bgr;-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis , 2018, JAMA.

[18]  O. Usmani,et al.  Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes , 2018, Respiratory Research.

[19]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[20]  T. H. Nguyen,et al.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.

[21]  A. von Leupoldt,et al.  [Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. , 2017, Pneumologie.

[22]  J. Weiler,et al.  Exercise-induced bronchoconstriction update-2016. , 2016, The Journal of allergy and clinical immunology.

[23]  E. Bateman,et al.  Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysis. , 2015, The Journal of allergy and clinical immunology.

[24]  J. Virchow,et al.  Severe asthma: definition, diagnosis and treatment. , 2014, Deutsches Arzteblatt international.

[25]  M. Sears Trends in the prevalence of asthma. , 2014, Chest.

[26]  F. Ducharme,et al.  Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. , 2014, The Cochrane database of systematic reviews.

[27]  R. Schmitz,et al.  Häufigkeit allergischer Erkrankungen in Deutschland , 2013, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[28]  Teresa To,et al.  Global asthma prevalence in adults: findings from the cross-sectional world health survey , 2012, BMC Public Health.

[29]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[30]  C. Jenkins,et al.  Measuring asthma control: a comparison of three classification systems , 2010, European Respiratory Journal.

[31]  T. Lasserson,et al.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. , 2010, The Cochrane database of systematic reviews.

[32]  D. Sin,et al.  Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. , 2006, European journal of pharmacology.

[33]  F. Ram,et al.  Physical training for asthma , 2014, Sao Paulo medical journal = Revista paulista de medicina.

[34]  P. Gibson,et al.  Long acting beta-agonists versus theophylline for maintenance treatment of asthma. , 2003, The Cochrane database of systematic reviews.

[35]  J. Kips,et al.  Cytokines in asthma , 2001, European Respiratory Journal.

[36]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .